Your browser doesn't support javascript.
loading
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Lockshin, Benjamin; Harrison, Ryan W; McLean, Robert R; Crabtree, Margaux M; Konicek, Bruce W; Zhu, Baojin; Malatestinic, William N; Atiya, Bilal; Murage, Mwangi J; Burge, Russel T.
Afiliación
  • Lockshin B; US Dermatology Partners, 15245 Shady Grove Road, Suite 480, Rockville, MD, 20850, USA. blockshin@dermassociates.com.
  • Harrison RW; CorEvitas, LLC, Waltham, MA, USA.
  • McLean RR; CorEvitas, LLC, Waltham, MA, USA.
  • Crabtree MM; CorEvitas, LLC, Waltham, MA, USA.
  • Konicek BW; Eli Lilly and Company, Indianapolis, IN, USA.
  • Zhu B; Eli Lilly and Company, Indianapolis, IN, USA.
  • Malatestinic WN; Eli Lilly and Company, Indianapolis, IN, USA.
  • Atiya B; Eli Lilly and Company, Indianapolis, IN, USA.
  • Murage MJ; Eli Lilly and Company, Indianapolis, IN, USA.
  • Burge RT; Eli Lilly and Company, Indianapolis, IN, USA.
Dermatol Ther (Heidelb) ; 12(12): 2797-2815, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36331713
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2022 Tipo del documento: Article